Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Novelix Pharmaceuticals Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts Novelix Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Novelix Pharma. - Shareholders Meeting- Notice Of Extra-Ordinary General Meeting Under Regulation 30 Of The SEBI (Listing Obl
-
Novelix Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended May 29, 2026
-
Novelix Pharma. - Announcement under Regulation 30 (LODR)-Preferential Issue
-
Novelix Pharma. - Shareholders Meeting - EGM On 01St July, 2026.
-
Novelix Pharma. - Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligations A
-
Novelix Pharma. - Announcement Under Regulation 30 (LODR) - Intimation Regarding The Execution Of An Agreement With GMBU\r\nE
-
Novelix Pharma. - Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Thursday, 04Th June, 2026 Purs
-
Novelix Pharma. - Announcement Under Regulation 30 (LODR)- Authorization Of Kmps Under Regulation 30(5) SEBI (LODR) Regulatio
-
Novelix Pharma. Q4 net profit zooms 405.56% at Rs 0.91 cr
-
Novelix Pharma. - Announcement Under Regulation 30 (LODR)- Re-Appointment Of Internal Auditor
-
Novelix Pharma. - Announcement under Regulation 30 (LODR)-Allotment
-
Novelix Pharma. - Compliances- Statement Of Deviation & Variation
-
Novelix Pharma. - Results- Financial Results For March 31, 2026
-
Novelix Pharma. - Board Meeting Outcome for Outcome Of The Board Meeting Held On 29Th May, 2026.
-
Novelix Pharma. - Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Friday, 29Th May, 2026.
-
Novelix Pharma. - Intimation Under Regulation 30 (LODR) Regulations, 2015- Website Address.
-
Novelix Pharma. - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Novelix Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Novelix Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Novelix Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended March 30, 2026
-
Novelix Pharma. - Announcement under Regulation 30 (LODR)-Allotment
-
Novelix Pharma. - Announcement under Regulation 30 (LODR)-Resignation of Director
-
Novelix Pharma. - Intimation Under Regulation 30 (LODR), Regulations 2015- Reconstitution Of Committees.
-
Novelix Pharma. - Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th April, 2026
Key fundamentals
Evaluate the intrinsic value of Novelix Pharmaceuticals Ltd stock
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 50.8103 | 26.8404 | 7.3547 | 7.1951 | 7.2431 |
| Liabilities | 50.8103 | 26.8404 | 7.3547 | 7.1951 | 7.2431 |
| Equity | 21.085 | 9.95 | 8.1 | 8.1 | 8.1 |
| Gross Profit | 3.4728 | 0.1453 | -0.2479 | -0.5179 | -2.0459 |
| Net Profit | 2.5566 | 0.0845 | 0.0104 | -0.0599 | -1.5603 |
| Cash From Operating Activities | -22.3891 | -13.6845 | -0.3434 | 0.0946 | 0.593 |
| NPM(%) | 1.93 | 0.27 | 0.24 | -4.26 | -185.04 |
| Revenue | 132.3062 | 30.7184 | 4.2237 | 1.4045 | 0.8432 |
| Expenses | 128.8334 | 30.5731 | 4.4717 | 1.9225 | 2.8891 |
| ROE(%) | 5.94 | 0.19 | 0.02 | -0.13 | -3.62 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Novelix Pharmaceuticals Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Sugal and Damani Share Brokers Ltd | 63.50 | 2.95 | 9.61 | 49.67 | 66.05 | 1.57 |
| 360 One Wam Ltd | 1131.10 | 3.24 | 37.79 | 3124.36 | 2991.91 | 0.00 |
| Arman Holdings Ltd | 107.60 | -1.56 | 58.80 | 41.41 | 18.23 | 0.00 |
| Asia Capital Ltd | 56.49 | -2.00 | 131.37 | 24.58 | 4.39 | 0.00 |
Company Info
Sri. Gopi krishna Bhangadia .B.com started Pharmaceutical distribution in 1976 by name Sri Datta Agencies. From past 30 years, the family is engaged in pharmaceutical business giving quality & good services to the society. Arun kumar Bangadia, son of Gopi krishna Bangadia floated the various companies among them one is TDPL. in the year 1994.And the directors are involved in Stock Broking Business . Company: The company is engaged in Manufacturing , distribution , Marketing , trading of pharmaceutical products and the company's branded products are already in the market and well accepted by doctors for it's quality The successful processes with specific needs allowed us to establish and add a broad range of products. The product range includes antibiotics, anti ulcer, anti inflammatory, anti tussive/expectorant, cardiovascular, anti fungal, anti retroviral drugs, syrups,. the protein powder. The company is planning to add liquids, Ayurvedic products shortly. The company has a highest co-operation with Institutional & Govt organizations. Strategy: Tie-ups and Collaborations, Joint Ventures, Buy Back Arrangements, Contractual Manufacturing, Turn Key Projects etc. We have adequate facility to supply any other formulation as per your specification on Demand. Export : The company is planning to export its products to Sri Lanka, Phillipines, African ,Gulf countries , where there is a demand & need for the drugs. 2008 -Company name has been changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd 2009 -Company has been appointed as authorised distributors on all India level for M/s. Livewell Food products, Salon Dist, Himachal Pradesh and M/s. ABLE, Pharma, Salon Dist, Himachal Pradesh. 2010 -The Company has recommended the dividend of 3% (Rs. 0.03) on the equity shares 2011 -The Company has recommended the dividend of 3% on the equity shares. -The Company started marketing of its products in the state of Assam. With this the Company marked its presence In the Eastern part of India. 2012 -The Company has entered into a Manufacturing Agreement with M/s. Bharat Parenterals Limited, Vadodara, Gujrat for exclusive manufacture of Company's 12 products for export. -The Company entered into Distribution Agreement with Zyanya Global Pte Limited, Vietnam for selling the Company's Products in Vietnam. -The Company has recommended the dividend of 3% on the equity shares. 2024 -The Company name has changed to Novelix Pharmaceuticals Ltd. from Trimurthi Ltd.
Sri. Gopi krishna Bhangadia .B.com started Pharmaceutical distribution in 1976 by name Sri Datta Agencies. From past 30 years, the family is engaged in pharmaceutical business giving quality & good services to the society. Arun kumar Bangadia, son of Gopi krishna Bangadia floated the various companies among them one is TDPL. in the year 1994.And the directors are involved in Stock Broking Business . Company: The company is engaged in Manufacturing , distribution , Marketing , trading of pharmaceutical products and the company's branded products are already in the market and well accepted by doctors for it's quality The successful processes with specific needs allowed us to establish and add a broad range of products. The product range includes antibiotics, anti ulcer, anti inflammatory, anti tussive/expectorant, cardiovascular, anti fungal, anti retroviral drugs, syrups,. the protein powder. The company is planning to add liquids, Ayurvedic products shortly. The company has a highest co-operation with Institutional & Govt organizations. Strategy: Tie-ups and Collaborations, Joint Ventures, Buy Back Arrangements, Contractual Manufacturing, Turn Key Projects etc. We have adequate facility to supply any other formulation as per your specification on Demand. Export : The company is planning to export its products to Sri Lanka, Phillipines, African ,Gulf countries , where there is a demand & need for the drugs. 2008 -Company name has been changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd 2009 -Company has been appointed as authorised distributors on all India level for M/s. Livewell Food products, Salon Dist, Himachal Pradesh and M/s. ABLE, Pharma, Salon Dist, Himachal Pradesh. 2010 -The Company has recommended the dividend of 3% (Rs. 0.03) on the equity shares 2011 -The Company has recommended the dividend of 3% on the equity shares. -The Company started marketing of its products in the state of Assam. With this the Company marked its presence In the Eastern part of India. 2012 -The Company has entered into a Manufacturing Agreement with M/s. Bharat Parenterals Limited, Vadodara, Gujrat for exclusive manufacture of Company's 12 products for export. -The Company entered into Distribution Agreement with Zyanya Global Pte Limited, Vietnam for selling the Company's Products in Vietnam. -The Company has recommended the dividend of 3% on the equity shares. 2024 -The Company name has changed to Novelix Pharmaceuticals Ltd. from Trimurthi Ltd.
Read More
Parent Organisation
Novelix Pharmaceuticals Ltd.
Founded
21/10/1993
Managing Director
NSE Symbol
FAQ
The current price of Novelix Pharmaceuticals Ltd is
The 52-week high for Novelix Pharmaceuticals Ltd is
The market capitalization of Novelix Pharmaceuticals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Novelix Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Novelix Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Novelix Pharmaceuticals Ltd shares.
The CEO of Novelix Pharmaceuticals Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
